Dec 9 (Reuters) - Eli Lilly said on Tuesday it will invest more than $6 billion in a new active drug ingredient manufacturing facility in Huntsville, Alabama, to expand U.S. production and bolster medicine supply chains.
The site, the third new U.S. facility announced by Lilly, will make small-molecule synthetic and peptide medicines, including orforglipron, its first oral GLP-1 weight-loss drug anticipated to receive U.S. approval early next year.
Global pharmaceutical companies have been increasing U.S. investments after President Donald Trump urged the industry to make more medicines domestically rather than importing active ingredients or finished medicines.
Earlier this year, Lilly outlined plans to spend at least $27 billion on four new U.S. manufacturing sites to counter potential drug import duties. Lilly said another location will be announced in the coming weeks.
The company said the construction is slated to begin in 2026, creating about 3,000 construction jobs, with completion targeted for 2032. Lilly also plans 450 roles for engineers, scientists, operations personnel and lab technicians in the area.
CEO David Ricks said the investment advances the onshoring of active pharmaceutical ingredient production to strengthen supply resilience.
The company estimates every dollar invested could generate up to four dollars in local economic activity.
The site was chosen from more than 300 applications, aided by proximity to the HudsonAlpha Institute for Biotechnology, an established bioscience campus supporting workforce training and research, Lilly said.
Alabama Governor Kay Ivey called the project "the largest initial investment in our state's history."
Lilly said the plant will use machine learning, AI and digitally integrated monitoring systems, with automation embedded across operations.
The company also aims to work toward carbon neutrality at the site, said Edgardo Hernandez, Lilly's manufacturing operations head.
(Reporting by Puyaan Singh in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Why is Jerome Powell being investigated? Making sense of the DOJ's probe into the Federal Reserve chair. - 2Mom warns of Christmas gift hazard as daughter recovers in hospital
- 3Impact of NIH funding reductions felt in cancer and infectious disease trials
- 4Carrefour becomes first European retailer to offer shopping on ChatGPT
- 5Affordable Care Act enrollment is slightly ahead of last year, despite expiring subsidies
- 5 Instructive Toy Brands for Youngsters
- New materials, old physics – the science behind how your winter jacket keeps you warm
- Chicago reports first rabies-positive dog in 61 years. What we know.
- Which restaurants and fast food chains will be open on Christmas Eve and Christmas Day?
- ‘Dying of thirst’: Inside Gaza’s al-Mawasi water crisis
- Hezbollah fires over 600 times at Israel, IDF troops over last 24 hours
- Journey Lines for Each Explorer: Track down Your Ideal Journey
- Humpback whale stranded on Germany's Baltic coast frees itself
- Ukrainian Army Converts E38 BMW 7-Series Into Multiple Rocket Launch Platform
